2026-2034年全球细胞和基因治疗临床试验市场规模、份额、趋势和成长分析报告

细胞和基因疗法临床试验的市场规模预计将从 2025 年的 128.1 亿美元增长到 2034 年的 461.7 亿美元，2026 年至 2034 年的复合年增长率为 15.31%。

细胞和基因疗法的临床试验领域正经历爆炸性增长，这反映了科学突破、监管政策变化以及对CAR-T疗法、基因编辑和病毒载体技术投资的增加。目前，肿瘤学、罕见遗传疾病和再生医学领域的试验正在进行，试验采用病毒和非病毒递送方式来引入、修饰或替换遗传物质。这一增长得益于孤儿药激励政策的优惠以及生物技术公司与大型製药公司之间日益密切的合作。

关键驱动因素包括载体设计和CRISPR/核苷酸编辑平台的技术进步、病毒载体和细胞处理生产能力的提升，以及在多种骨髓恶性肿瘤中征兆出的显着临床疗效。法规结构提供的快速核准管道和仿单标示外用药方案正在加速临床试验的启动。此外，临床试验网络的完善和专业製造地的建设正在缩短患者用药时间，并支持多中心合作研究。

未来前景广阔但也错综复杂。拓展至固体癌、提升安全性以及建立可扩展的生产系统仍然是至关重要的挑战。新一代递送系统、现成的异体细胞疗法以及体内基因编辑技术可望拓展适应症并降低成本。长期安全性监测和克服生产瓶颈预计将决定其商业性可行性。如果技术和物流方面的挑战得以解决，细胞和基因疗法有望从一种小众、高成本的治疗方法方法转变为更广泛适用的根治性选择。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球细胞与基因治疗临床试验市场：依阶段划分

• 市场分析、洞察与预测
• 第一阶段
• 第二阶段
• 第三阶段
• 第四阶段

第五章：全球细胞与基因治疗临床试验市场：依适应症划分

• 市场分析、洞察与预测
• 肿瘤学
• 心臟病学
• 中枢神经系统
• 肌肉骨骼系统
• 感染疾病
• 皮肤科
• 内分泌、代谢和遗传性疾病
• 免疫学与炎症
• 眼科
• 血液学
• 胃肠病学
• 其他的

第六章 全球细胞与基因治疗临床试验市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 以色列
  • 南非
  • 其他中东和非洲国家

第七章 竞争情势

• 最新趋势
• 公司分类
• 供应链和分销通路合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第八章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Iqvia
  • ICON Plc
  • Laboratory Corporation Of America Holdings
  • Charles River Laboratories International Inc
  • Parexel International Corp
  • Syneos Health
  • Medpace Holdings Inc
  • PPD Inc
  • Novotech
  • Veristat LLC

The Cell And Gene Therapy Clinical Trials Market size is expected to reach USD 46.17 Billion in 2034 from USD 12.81 Billion (2025) growing at a CAGR of 15.31% during 2026-2034.

The cell and gene therapy clinical trials landscape has grown explosively, reflecting scientific breakthroughs, regulatory pathways, and rising investment in CAR-T, gene-editing, and viral-vector technologies. Trials span oncology, rare genetic disorders, and regenerative medicine, leveraging viral and non-viral delivery methods to introduce, modify, or replace genetic material. Growth has been bolstered by favorable orphan-drug incentives and increasing partnerships between biotech firms and large pharma sponsors.

Key drivers include technological advances in vector design, CRISPR and base-editing platforms, improved manufacturing capabilities for viral vectors and cell processing, and strong clinical efficacy signals in several hematologic malignancies. Regulatory frameworks that offer accelerated pathways and compassionate-use programs have encouraged trial initiation. Additionally, improved trial networks and specialized manufacturing hubs shorten time-to-patient and support multi-center studies.

Future prospects are substantial but complex: expansion into solid tumors, broader safety profiling, and scalable manufacturing remain critical challenges. Next-generation delivery systems, off-the-shelf allogeneic cell therapies, and in vivo gene-editing promise to expand indications and lower costs. Long-term safety monitoring and addressing manufacturing bottlenecks will determine commercial viability. If technical and logistical hurdles are solved, cell and gene therapies could transition from niche, high-cost treatments to more widely available curative options.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Phase

• Phase I
• Phase II
• Phase III
• Phase IV

By Indication

• Oncology
• Cardiology
• CNS
• Musculoskeletal
• Infectious Diseases
• Dermatology
• Endocrine, Metabolic, Genetic
• Immunology & Inflammation
• Ophthalmology
• Hematology
• Gastroenterology
• Others

COMPANIES PROFILED

• Iqvia, ICON Plc, Laboratory Corporation of America Holdings, Charles River Laboratories International Inc, Parexel International Corp, Syneos Health, Medpace Holdings Inc, PPD Inc, Novotech, Veristat LLC
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CELL AND GENE THERAPY CLINICAL TRIALS MARKET: BY PHASE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Phase
• 4.2. Phase I Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Phase II Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Phase III Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Phase IV Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CELL AND GENE THERAPY CLINICAL TRIALS MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Cardiology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. CNS Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Musculoskeletal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Dermatology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Endocrine, Metabolic, Genetic Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Immunology & Inflammation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.10. Ophthalmology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.11. Hematology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.12. Gastroenterology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.13. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CELL AND GENE THERAPY CLINICAL TRIALS MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Phase
  • 6.2.2 By Indication
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Phase
  • 6.3.2 By Indication
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Phase
  • 6.4.2 By Indication
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Phase
  • 6.5.2 By Indication
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Phase
  • 6.6.2 By Indication
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL CELL AND GENE THERAPY CLINICAL TRIALS INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Iqvia
  • 8.2.2 ICON Plc
  • 8.2.3 Laboratory Corporation Of America Holdings
  • 8.2.4 Charles River Laboratories International Inc
  • 8.2.5 Parexel International Corp
  • 8.2.6 Syneos Health
  • 8.2.7 Medpace Holdings Inc
  • 8.2.8 PPD Inc
  • 8.2.9 Novotech
  • 8.2.10 Veristat LLC